PRFX — PRF Technologies Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1801834 ·
Israel
Last close
$1.34
Market Cap
$1.16M
52W High
$3.17
52W Low
$1.28
ADV30
183,339
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 11,998,000 | 3,125,000 | 2,708,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-61,289,000
Inventory
—
Receivables
$142,000
ST Investments
$1,016,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$17,000
EBITDA
$-4,348,000
Free Cash Flow
$-2,002,250
Enterprise Value
$-2,114,885
Total Cash
$4,141,000
Total Debt
$21,000
Shares Out
868,756
Trailing EPS
$-7.47
Book Value
$10.29
ROE
-90.4%
ROA
-38.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 17,000 | -5,122,000 | -5,022,000 | 11,998,000 | 2,708,000 | — | -3,955,000 |
| Dec 2024 | 0 | -14,673,000 | -14,588,000 | 4,525,000 | 2,701,000 | — | -12,621,000 |
| Dec 2023 | 0 | -9,584,000 | -9,344,000 | 9,930,000 | 2,691,000 | — | -6,679,000 |
| Dec 2022 | 0 | -8,869,000 | -8,792,000 | 12,328,000 | 1,307,000 | — | -6,459,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-12.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ISCO | International Stem Cell CORP | $1.36M | $0.17 | — |
| ONCO | Onconetix, Inc. | $1.44M | $1.26 | — |
| ZVSA | ZyVersa Therapeutics, Inc. | $1.46M | $0.18 | — |
| SKVI | SKINVISIBLE, INC. | $924.6K | $0.17 | — |
| EVFM | Evofem Biosciences, Inc. | $874.7K | $0.01 | — |
News headlines (Yahoo Finance, 1h cache)
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
2026-05-26 12:30 · Yahoo
EXCLUSIVE: PRF Technologies Advances Drop-Less Drug For Cataract Surgery Pain
2026-05-01 02:31 · Yahoo
PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial
2026-04-28 12:00 · Yahoo
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms
2026-03-27 12:00 · Yahoo
PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements
2026-03-17 12:30 · Yahoo
PRF Technologies’ DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy
2026-02-18 14:15 · Yahoo
PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar’s Installed Commercial Base
2026-02-11 13:30 · Yahoo
PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy
2026-01-20 14:05 · Yahoo
PainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy Platforms
2026-01-15 21:05 · Yahoo
PainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies
2026-01-12 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.